TetraGenetics Partners with LifeArc to Humanize New Drugs and Perform IND-Enabling Studies

TetraGenetics, a biopharmaceutical company developing novel therapeutics for autoimmune diseases and pain, today announced a partnership with LifeArc^®, the UK-based medical research charity. The collaboration brings together the drug discovery skills of TetraGenetics with the antibody humanization and development capabilities of LifeArc. Under the agreement LifeArc will humanize up to five new drug leads discovered by TetraGenetics and may support pre-IND (Investigational New Drug) studies for selected programs. TetraGenetics will manage the regulatory applications and the subsequent clinical trials for successful candidates. Read more >>